Antiosteoporotic agent
Antiosteoporotic agent has been studied in 1 paper since 2016: 1 observational study in people. The newest paper, Nov 23, 2016: “Polypharmacy and adverse outcomes after hip fracture surgery”.
1 paper studies it1 findingUpdated
See all 1 papers on antiosteoporotic agent
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“use of antiosteoporotic agents, SSRIs, and eye drops predicted rehospitalization after hip fracture surgery”
Humans: a single group. Cells, worms or flies and mice: nothing yet.
- 1 lab in 1 country
- Funders: Crafoordska Stiftelsen and 5 more
- Humans1
What is antiosteoporotic agent linked with?
1Studies link antiosteoporotic agent with rehospitalization.
Rehospitalization
upin humans1OR 1.86
1 study
Rehospitalization
upin humans1OR 1.86
Antiosteoporotic agent predicts rehospitalization in humans after hip fracture surgery (OR 1.86, 95% CI 1.06–3.26).
Humansafter hip fracture surgery6 months after discharge72.1% femalessn = 272
Latest
Journal of Orthopaedic Surgery and Research
Polypharmacy and adverse outcomes after hip fracture surgery
Cohort study of 272 peopleHip fracture